← Russell 3000 cross-section

QDEL QuidelOrtho Corp

Trailing twelve months to 2026-06-28 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$1.1bn
Revenue TTM
$2.7bn
Net income TTM
$-1.0bn
Free cash flow
$-211m
Composite score
16.3
Sector rank
#1990

Valuation

P / E
EV / EBITDA
EV / sales
0.5
FCF yield
-20.01%
Earnings yield vs 10-yr
-104.07pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-39.2%
EBITDA margin
-13.8%
ROE
-59.1%
ROIC
-41.1%
Revenue growth
-2.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We also generate non-core revenue, including through our contract manufacturing business and certain business collaborations, which accounted for $54.4 million and $59.8 million for the six months ended June 28, 2026 and June 29, 2025, respectively. For the six months ended June 28, 2026, Total revenues decreased by 4% to $1,250.7 million as compared to the same period in the prior year. This decrease was primarily driven by (i) variability of our U.S. respiratory products, mainly due to decreases in flu and COVID-19 revenues, (ii) the termination of our Joint Business arrangement and (iii) evolving market dynamics in China. The winding-down of the U.S. …QuidelOrtho Corp, 10-Q, period ended 2026-06-28, filed 2026-08-07

Read the full passage →